30 results about "Thyroid hormones" patented technology

The invention relates to an application of a DIO1 gene in a liver in controlling the body color of a turbot, and belongs to the field of molecular biology, and the application method is as follows: the turbot with golden body color is obtained by overexpressing the DIO1 gene in the liver of the turbot; the amino acid sequence of the protein coded by the DIO1 gene is as shown in SEQ ID NO. 1. The invention discovers that the gene expression level change in the liver can cause the change of the blood hormone level by influencing the thyroid hormone pathway in the turbot for the first time, thereby influencing the color formation of the skin; therefore, the formation of the target body color of the scophthalmus maximus can be controlled by controlling the gene expression level, so that the market value of the scophthalmus maximus is improved.

The present invention discloses a composition for treating hypothyroidism. The formula includes: placenta, antler, Pseudostellaria baicalensis, Salvia miltiorrhiza, and Herba Lycopodii. The prescription of the present invention is demonstrated to have therapeutic effects on hypothyroidism from both traditional Chinese medicine and modern medicine perspectives: from the perspective of traditional Chinese medicine, the efficacy of the present invention in replenishing qi and blood, regulating yin and yang, tonifying kidney essence, filling the marrow sea, and unblocking meridians is unique in treating goiter. From the perspective of modern medicine: Panlushending Jiawei Decoction has the effects of promoting cell reproduction, differentiation, and repairing damaged cells, and is also anti-apoptotic. It also has the effects of promoting the regeneration of vascular endothelial cells, forming new blood vessels, increasing blood flow rate, increasing blood supply, and increasing the secretion and synthesis of thyroid hormones. It can also increase the level of free hormone reabsorption from the intestine and lower the concentration of antibodies.

Solid orodispersible compositions in the form of thin films for the oral administration of thyroid hormones are described, characterized by a high stability, and by the bioavailability of the active ingredient for oral absorption. The film compositions described are designed for rapid disintegration in the mouth, for sublingual administration, or to be held in the mouth for longer times before they disintegrate, but in any case without being mucoadhesive films. All the examples described are characterized by being thin and flexible and are suitable for administration even to patients who are not conscious, dysphagic or otherwise unable to swallow.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The invention relates to pyridazinone or pyridazine compounds as well as derivatives and pharmaceutical compositions thereof. Specifically, the invention provides a pyridazinone or pyridazine compound as shown in a formula (I) or (Ia) or a stereoisomer, a tautomer, an enantiomer, a diastereoisomer, a resonator, a pharmaceutically acceptable salt, a hydrate, a solvate or a crystal form of the pyridazinone or pyridazine compound. The compound shown in the formula (I) or (Ia) has excellent agonistic effect and pharmacodynamic performance on a thyroid hormone beta receptor.

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.

The present invention relates to a polycyclic thyroid hormone β receptor agonist and use thereof, in particular, to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, a preparation method therefor, and use thereof. The compound or the pharmaceutical composition of the present invention can be used for preparing a drug for preventing, treating, or relieving diseases regulated by the thyroid hormone β receptor.

The present application relates to a kind of thyroid hormone interferent high-sensitivity screening method, belong to new pollutant screening method technical field.The present application is based on the biological recognition performance of polypeptide and the peroxidase-like activity of nano gold combined with polypeptide material, based on this, a kind of thyroid hormone interferent screening method under medium alkaline condition can guarantee the activity of polypeptide and also can play the enzyme activity of nano gold.The dopamine can be catalyzed by nano gold under medium alkaline condition and quickly generate red product.Once interferent combines specific recognition polypeptide, occupies the enzyme activity recognition site of nano gold, reduces enzyme activity, in dopamine color system, different absorbance values are shown, so as to show the thyroid hormone interference toxic effect, reach the purpose of recognizing thyroid hormone interferent.The method does not need to use a large amount of organic solvent, and toxicity evaluation of thyroid hormone interferent can be realized by absorbance determination, with the advantages of simple preparation, low cost, high sensitivity.

Disclosed in the present invention is a thyroid hormone β receptor agonist, which is a compound having a structure represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.

The present disclosure provides methods and a device for thyroxine delivery. This device is designed for subcutaneous implantation to ensure continuous delivery of thyroxine. It features a reservoir regulated by an embedded microprocessor with advanced signal software. The software triggers a precision pump to release a specific dose of thyroxine at regular intervals. This system enhances patient compliance and maintains optimal metabolic control.

The present invention provides a preparation method for Resmetirom and an intermediate I thereof. In the method, by means of a continuous process, there is no need to separate the intermediate and perform post-reaction work-up, thereby saving a plurality of procedures and operation time; and the work-up is simple and efficient, and the use of a highly polluting reagent pyridine is avoided. Moreover, by adjusting a material feeding order, the reaction can be promoted and the color of a product can be effectively improved. The entire process is simple to operate and cost-effective, uses a green and environmentally friendly reagent, and is suitable for large-scale industrial production.

The present disclosure provides methods of treating a medulloblastoma in a subject in need comprising administering T3 to the subject. The present disclosure also provides methods of inhibiting proliferation of medulloblastoma cells in a subject in need by administering T3 to the subject. Moreover, the present disclosure provides uses of T3 for treating medulloblastoma and the manufacture of a medicament for treating medulloblastoma.

The invention provides a culture medium and a culture method of a hiPSC-derived thyroid organ, and belongs to the technical field of thyroid organ culture. The invention relates to a culture method of a hiPSC-derived thyroid organ. The culture method comprises the following steps: (1) putting a resuscitated hiPSC-derived thyroid organ into a proliferation culture medium for culturing; and (2) when the thyroid organoid is cultured in the step (1) until the size of the thyroid organoid is 120-150 microns, replacing the proliferation culture medium with a differential culture medium, and continuously culturing. Sodium iodide with a specific concentration is added during thyroid organoid culture, so that the secretion amount of in-vitro thyroxine T4 of the organoid reaches 5ng / ml and is far higher than that (0.023 ng / ml) in the prior art. The invention provides a culture medium and a culture method capable of obviously promoting the maturity of the thyroid organoid, and the culture medium and the culture method have a wide application prospect.

Provided are a group of fully human thyrotropin receptor (TSHR) (TSH receptor, TSHR) blocking monoclonal antibodies belonging to a SH1 homocluster, a preparation method therefor, and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and individual memory B cells, which specifically recognize TSHR, from peripheral blood of a patient having a high TSH receptor blocking antibody (TBAb) titer, cloning antibody light and heavy chains in vitro, followed by recombinant expression, and performing antibody characteristic screening and verification by using hTSHR-CHO cells, thereby obtaining blocking monoclonal antibodies that specifically target human TSHR. The fully human TSH receptor blocking monoclonal antibodies can specifically bind to TSHR, thereby enabling effective blockage of signal transduction after TSH binds to the receptor, inhibiting the synthesis and secretion of thyroid hormones, and significantly reducing and suppressing the expression of TSHR and fibrosis in orbital fibroblasts, the effector cells in thyroid-related eye diseases. The present invention has broad application prospects in the treatment of Graves' diseases and diseases caused by hyperthyroidism, such as thyroid eye diseases.

Methods of treatment of medulloblastoma by administering thyroid hormone (T3) to a subject are provided herein.

The invention relates to the technical field of in-vitro diagnosis, in particular to a thyroid hormone detection kit and a thyroid hormone detection method. Wherein the thyroid hormone comprises at least one of triiodothyronine and tetraiodothyronine; the thyroid hormone detection kit comprises (i) a cyclodextrin reserve reagent; ii) an antibody capture reagent; iii) an antibody detection reagent; and, iv) a signalling agent. According to the kit and the detection method, the T3 and T4 detection signal intensity can be improved, the detection limit is reduced, and the accuracy and reliability of low-concentration sample detection are improved.

The invention provides application of thyroxine and a thyroxine receptor inhibitor in preparation of a medicine for regulating primordial follicle activation, and belongs to the technical field of biology. It is found that thyroxine can promote primordial follicle activation, the thyroxine receptor inhibitor inhibits primordial follicle activation, and the thyroxine receptor inhibitor can serve as a medicine for adjusting primordial follicle activation of a patient suffering from premature ovarian insufficiency and has a good application prospect.

The invention provides application of SLC16A10 in diagnosis and treatment of psoriasis, and relates to the technical field of biological medicines. The research of the inventor finds that SLC16A10 can participate in metabolism of arachidonic acid in keratinocytes by adjusting the homeostasis of thyroid hormones so as to promote the occurrence and development of psoriasis; the SLC16A10 represents a promising therapeutic target for treating psoriasis drip, and can improve the curative effect of the existing immune targeted therapeutic drug; comprehensive in-vitro and in-vivo experiments prove that the severity and excessive inflammation of psoriasis can be relieved by down-regulation of the SLC16A10; in addition, the SLC16A10 can induce one of sequelae of psoriasis, namely post-inflammation hypopigmentation, by inhibiting melanogenesis. Research results of the invention show that the SLC16A10 has potential as a psoriasis diagnosis biomarker and a treatment target.

This invention provides a mesenchymal stem cell culture medium, its preparation method, and its application. The mesenchymal stem cell culture medium of this invention includes a basal culture medium and functional additives. The functional additives include: recombinant human albumin, recombinant transferrin, recombinant bone morphogenetic protein; recombinant insulin or insulin-like growth factor, recombinant fibroblast growth factor, recombinant epidermal growth factor, recombinant platelet-derived growth factor; thyroid hormones, ethanolamine, carnitine, glucocorticoid regulators, retinoic acid compounds; heparin sodium, signal-regulating lipids, cholesterol, DL-α-tocopherol acetate, linolenic acid, oleic acid, stearic acid; prolactin F68, and Tween 80. The mesenchymal stem cell culture medium of this invention does not contain immunogenic proteins or blood products derived from animals or humans. All components can be supplied with GMP-compliant raw materials and the process can be controlled, ensuring the controllability, safety, and reproducibility of the culture process.

The present disclosure belongs to the field of medicines. Disclosed in the present invention are a thyroid hormone β receptor agonist, a crystalline form, a preparation method and the use. The compound is a compound having a structural formula as represented by formula (I) or a pharmaceutically acceptable salt thereof. The X-ray powder diffraction pattern of a crystal form A of the compound of formula (I) comprises characteristic peaks at 6.10 ± 0.20°, 12.08 ±0.20° and 16.49±0.20° 2θ, as determined by means of using Cu-Ka radiation, The present invention develops a new 2-pyridone derivative. The compound has high agonistic activity and selectivity for the thyroid hormone β receptor, and can be used for treating metabolic diseases, particularly for treating diseases related to thyroid hormone receptor. The present invention also studies a series of crystal forms of the compound. The crystal form A compound has the advantages of good stability, low hygroscopicity, and small heat influence.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to application of a traditional Chinese medicine composition in preparation of medicine for treating thyroiditis, and the traditional Chinese medicine composition is mainly prepared from codonopsis pilosula, radix astragali preparata, poria cocos, fried rhizoma atractylodis macrocephalae, prepared polygala tenuifolia, honey-fried licorice root, fried spina date seed, longan aril, angelica sinensis, jujube, elecampane and ginger. All the medicines in the traditional Chinese medicine composition conform to the principle of compatibility of monarch, minister, assistant and guide, compatibility is scientific, clinical cases are considered, pharmacodynamic tests show that the composition can remarkably improve the basic condition of mice suffering from thyroiditis, adjust the levels of thyroid hormones T3, T4 and TSH of the mice, reduce inflammatory factors TNF-alpha and IL-10 and inhibit inflammatory reaction, and clinical tests verify that the composition has a remarkable curative effect on thyroiditis. The traditional Chinese medicine composition can effectively relieve symptoms of patients with thyroiditis, is low in toxic and side effects and good in safety, and has a wide market prospect.

Provided are a polycyclic thyroid hormone β receptor agonist and the use thereof. Specifically, the present invention relates to a compound as represented by formula (1) or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The compound or pharmaceutical composition can be used for the preparation of a drug for preventing, treating or alleviating diseases regulated by the thyroid hormone β receptor.

This document provides anti-thyroxine transporter (TTR) antibodies, corresponding polynucleotides and expression vectors, and compositions (e.g., pharmaceutical compositions) containing anti-TTR antibodies as drugs, and related articles. This document also provides methods for treating or preventing thyroxine transporter-mediated amyloidosis (ATTR) in subjects of need using pharmaceutical compositions. Additionally, this document provides methods for validating, identifying, and screening amyloid depletion drugs using high-resolution live-cell imaging, methods for generating pharmaceutical compositions of amyloid depletion drugs, and kits suitable for said methods.

The present disclosure belongs to the field of medicines. A thyroid hormone β receptor agonist, a crystalline form, a preparation method and the use thereof are provided. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The X-ray powder diffraction pattern of a crystal form A of the compound of formula (I) comprises characteristic peaks at 6.10±0.20°, 12.08±0.20° and 16.49±0.20° 20, as determined by means of using Cu-Kα radiation. The present invention develops a new 2-pyridone derivative. The compound has high agonistic activity and selectivity for the thyroid hormone β receptor, and can be used for treating metabolic diseases, particularly for treating diseases related to thyroid hormone receptor. The present invention also studies a series of crystal forms of the compound. The crystal form A compound has the advantages of good stability, low hygroscopicity, and small heat influence.

Disclosed are crystal of thyroid hormone β receptor agonist, process for preparing the same and use thereof. The crystal with basically no hygroscopicity, a relatively small crystal particle size and a relatively large drug specific surface area can improve the dissolution rate of drugs, is beneficial to the absorption of drugs and improves the bioavailability.

The invention provides application of C. sporogenes or supernate thereof in preparation of a medicine for preventing and / or treating Graves disease, and belongs to the technical field of biological medicine. The research finds that after intervention of C.sporogenes and supernate thereof, thyroid hormones FT4 and TRAb of a mouse suffering from Graves disease are obviously reduced, TSH is increased, serum inflammation anti-inflammatory factors are increased, proinflammatory factors are reduced, body weight is increased, and food intake is reduced; the colon tissue structure is complete, columnar epithelial cells of the epithelial layer are arranged in order, cup-shaped cells are evenly distributed and moderate in number, colon villus is complete, a small amount of panesian cells can be seen in crypts, thyroid tissue follicles are normal in structure and are oval or round, the follicles are different in size, the epithelial cells are in a single-layer flat shape and are arranged in order, and the follicles contain rich colloid. The Graves disease can be effectively treated.

Provided is a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be used in the preparation of drugs for preventing, treating or mitigation of diseases mediated by agonistic thyroid hormone β receptor, particularly for the preparation of drugs for treating non-alcoholic fatty liver diseases.

The invention discloses a thyroxine interferent cell screening method based on a fluorescent probe and application, and relates to the technical field of new pollutant screening methods. The method comprises the following steps: transfecting JEG3 cells through lentivirus LV-MCT8, and constructing a JEG3-MCT8 stably transfected cell line; after co-incubating the cells, a fluorescent probe and pollutants with different concentrations, detecting the change of a fluorescence value by utilizing a flow cytometer; the fluorescent probe is used as a thyroxine simulant and can be transferred into cells by MCT8 protein; if the pollutant is a thyroxine interferent, the pollutant can be competitively combined with MCT8 protein to occupy a transport site, so that the fluorescent probe intake of cells is reduced, and the fluorescence value is reduced, thereby achieving the purpose of screening the thyroxine interferent; the method gets rid of the limitation of 125I-T3 radioactive tracers, avoids isotope decay, shelf life limitation and potential health risks, has the characteristics of simplicity, safety, convenience and the like, and provides powerful technical support for screening of thyroxine interferents.